Needham & Company LLC Reaffirms “Hold” Rating for TransMedics Group (NASDAQ:TMDX)

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports. They currently have a $109.00 price objective on the stock. Needham & Company LLC’s price target suggests a potential upside of 37.38% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the stock. TD Cowen reduced their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group lowered their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday. Piper Sandler reduced their price target on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, JPMorgan Chase & Co. lowered their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Trading Up 2.8 %

NASDAQ TMDX opened at $79.34 on Friday. The stock has a market cap of $2.66 billion, a P/E ratio of 84.41 and a beta of 2.08. TransMedics Group has a fifty-two week low of $67.77 and a fifty-two week high of $177.37. The stock has a 50 day simple moving average of $120.68 and a two-hundred day simple moving average of $138.09. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue was up 63.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.12) EPS. On average, analysts forecast that TransMedics Group will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This trade represents a 12.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock worth $5,230,528 over the last quarter. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently modified their holdings of the business. Morse Asset Management Inc bought a new position in TransMedics Group in the 3rd quarter worth $823,000. Virtu Financial LLC purchased a new stake in TransMedics Group in the third quarter worth about $436,000. Neo Ivy Capital Management bought a new position in shares of TransMedics Group in the third quarter worth about $554,000. Geode Capital Management LLC lifted its position in shares of TransMedics Group by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after buying an additional 10,106 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $368,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.